Skip to content
HLTH 5391

Special Authority Request, Dabigatran for Atrial Fibrillation

Dabigatran is a limited coverage drug in BC, while apixaban and rivaroxaban are regular benefits. HLTH 5391 asks you to show non-valvular AF with at least one CHADS2 risk factor and a reason warfarin isn't suitable, and approval is indefinite.

At a glance

Checked October 2026

Form number
HLTH 5391
Issued by
BC PharmaCare, Ministry of Health
Where
British Columbia
Completed by
Prescriber
Format
Fillable PDF, or Special Authority eForm
Language
English

What the HLTH 5391 is for

HLTH 5391 requests PharmaCare coverage of dabigatran 110 mg or 150 mg for stroke and systemic embolism prevention in non-valvular atrial fibrillation. Because apixaban and rivaroxaban are regular benefits, PharmaCare expects a specific reason for dabigatran, and the form asks for it through the warfarin criteria.

Who completes it

The prescriber completes and signs the request. No specialty is exempt.

How to fill in the request

Sections 1 and 2, prescriber and patient information

Enter your name, mailing address, phone, fax and college ID only, and the patient’s names, date of birth, date of application and PHN.

Section 3, medication and dose selection

Select dabigatran and the strength. The form’s dosing note recommends 110 mg twice daily for creatinine clearance or eGFR of 30 to 49 mL/min and 150 mg twice daily at 50 mL/min or more. PharmaCare’s criteria page also notes the product monograph recommends 110 mg twice daily from age 80.

Section 4A, diagnosis and risk factors

Confirm non-valvular AF, without hemodynamically significant rheumatic valvular disease or a prosthetic valve, and check at least one CHADS2 risk factor: heart failure, hypertension, age 75 or older, diabetes, or prior stroke or TIA. For patients 75 and older, renal function must have been adequate and stable for at least three months. Have the eGFR history in front of you before you sign.

Section 4B, why warfarin isn’t suitable

Check one reason: INR out of range on at least 35% of tests after at least two months of warfarin, inability to monitor INR regularly, or another reason explained in as much detail as you can. Sign in Section 5.

Common reasons it’s sent back

  • No CHADS2 risk factor checked.
  • A patient 75 or older with no documented stable renal function.
  • A warfarin trial shorter than two months, or no time-in-range figure.
  • An “other” reason that doesn’t explain why warfarin, or a regular benefit alternative, won’t work.
  • Missing fax number, college ID or signature.

Submitting and who pays

Dabigatran is eligible for automatic approval when submitted through Special Authority eForms. You can also fax the form to 1-800-609-4884, which takes longer and isn’t auto-adjudicated. Coverage starts when the approval is entered on PharmaNet. The patient pays according to their PharmaCare plan and deductible.

Get the official form

Download the current version from BC PharmaCare, Ministry of Health each time. Forms change without notice, and an old edition can be returned.

Official page ↗ PDF ↗

Medulla Forms

Fill HLTH 5391 from the visit and the chart.

Upload the fillable PDF to your practice's forms once. Medulla fills it from the visit and the chart open in your EMR, leaves blank anything the record doesn't support, and opens the form for your review. When it's done, save it to the patient's chart in one click.

Free 1-month trial. No credit card required.

Sources for this guide

Questions

Questions we hear a lot.

Do apixaban and rivaroxaban need Special Authority in BC?

No. The form notes that apixaban and rivaroxaban are PharmaCare regular benefits. HLTH 5391 applies to dabigatran only.

What counts as a failed warfarin trial for dabigatran coverage?

After at least two months of warfarin, INR results outside the desired range for at least 35% of tests. Inability to monitor INR regularly, with no access to testing at a lab, clinic, pharmacy or home, also qualifies.

Which patients are excluded from dabigatran coverage?

Patients with creatinine clearance or eGFR under 30 mL/min, patients 75 or older without documented stable renal function, and patients with hemodynamically significant rheumatic valvular disease or prosthetic heart valves.

How long is dabigatran approved for?

Indefinitely. There are no practitioner exemptions, so every prescriber who wants coverage submits the request.

Is patient information secure?

Yes. Medulla has a SOC 2 Type II report from an independent auditor, is HIPAA, PIPEDA, and PHIPA compliant, and is built and hosted in Canada, so patient data stays in the country and never gets pasted into consumer AI tools. Everything is encrypted in transit and at rest. See how we protect patient data.

More questions? Browse help.medulla.ca.